- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05706831
Musikintervention und transkranielle Elektrostimulation bei neurologischen Erkrankungen
Musikintervention und transkranielle Elektrostimulation zur Behandlung neurologischer Erkrankungen
The goal of this clinical trial is to evaluate the efficacy of a musical interventionand non-invasive brain stimulation in neurological patients. The main questions it aims to answer are:
- to evaluate the residual neuroplastic processes in DOC state related to music exposure
- to determine the putative modulation of the aforementioned processes and the clinical outcome of DOC patients by non-pharmacological strategies, i.e., electric (tDCS) and music stimulation
- to evaluate the impact of this intervention on caregiver's burden and psychological distress.
Participants will be randomly assigned to one of three different music-listening intervention groups. Primary outcomes will be clinical, that is based on the neurologist's observations of clinical improvement, and neurophysiological, collected pre-intervention, post-intervention and post-placebo.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Simona Spaccavento
- Telefonnummer: +393332783524
- E-Mail: simona.spaccavento@icsmaugeri.it
Studienorte
-
-
Ba
-
Bari, Ba, Italien, 70025
- Rekrutierung
- Istituti Clinici Scientifici Maugeri
-
Kontakt:
- Simona Spaccavento
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age > 18 years
- Post-stroke aphasia
- Post-stroke neglect
- Patients with disorders of consciusness (DOC)
Exclusion Criteria:
- No auditory injury
- no hystory of neurological disease
- No hystory of psychiatric disease
- Previous stroke
- use of alcohol and drugs
- premorbid dementia
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Group 1
Group 1 will receive tEs combined with music stimulation for 2 weeks, 1 week of wash out, then sham stimulation combined with noise (placebo) for other 2 weeks. |
music |
|
Experimental: Group 2
Group 2 will receive sham stimulation and noise (placebo) for the first 2 weeks, then 1 week wash out, and finally tEs and music stimulation for other 2 weeks. |
music |
|
Experimental: Group 3
Group 3 will receive only music stimulation and sham stimulation for 2 weeks, 1 week of wash out, then sham stimulation and noise (placebo) for another 2 weeks. |
music |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Coma Recovery Scale- Revised at 2 weeks and 4 weeks
|
-Coma Recovery Scale-Revised (CRS-R) - (0-23). High score means a better outcome. |
Change from baseline Coma Recovery Scale- Revised at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Disability Rating Scale at 2 weeks and 4 weeks
|
Disability Rating Scale (DRS) - (0-29). High score means a worse outcome. |
Change from baseline Disability Rating Scale at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Rancho Levels of Cognitive Functioning at 2 weeks and 4 weeks
|
Rancho Levels of Cognitive Functioning (LCF) - (1-8). High score means a better outcome. |
Change from baseline Rancho Levels of Cognitive Functioning at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Glasgow Outcome Scale- Extended at 2 weeks and 4 weeks
|
Glasgow Outcome Scale- Extended (GOS-E) - (1-8). High score means a better outcome. |
Change from baseline Glasgow Outcome Scale- Extended at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Aachener Aphasie Test at 2 weeks and 4 weeks
|
Aachener Aphasie Test (AAT). This test includes six subtests: spontaneous speech, token test, repetition, written language, naming, and comprehension. Spontaneous speech is structured in six parts (0-30). High score means a better performance; Token test is composed by 50 items; for the score the number of error id considered (0-50). Repetition sub test is composed by 50 items; for each item the score range from 0 to 3; high score means better outcome (0-150). Written language subtest is composed by 30 items; for each item the score range from 0 to 3; high score means better outcome (0-90). Naming subtest is composed by 40 items; for each item the score range from 0 to 3; high score means better outcome (0-120). Comprehension subtest is composed by 40 items; for each item the score range from 0 to 3; high score means better outcome (0-120). |
Change from baseline Aachener Aphasie Test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Italian version of Functional Outcome Questionnaire for Aphasie at 2 weeks and 4 weeks
|
Italian version of Functional Outcome Questionnaire for Aphasie (FOQ-A) - (32-160). High score means a better outcome. |
Change from baseline Italian version of Functional Outcome Questionnaire for Aphasie at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Functional Assessment Measure - Cognitive subscale at 2 weeks and 4 weeks
|
Functional Assessment Measure - Cognitive subscale - (FAM) - (14-98); high score means a better outcome. |
Change from baseline Functional Assessment Measure - Cognitive subscale at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Quality of Life Questionnaire for aphasics at 2 weeks and 4 weeks
|
Quality of Life questionnaire for Aphasics (QLQA) - (0-148); High score means a better outcome. |
Change from baseline Quality of Life Questionnaire for aphasics at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline The semi-structured scale for functional evaluation of personal neglect at 2 weeks and 4 weeks
|
The semi-structured scale for functional evaluation of personal neglect - (0-9); High score means a worse outcome. |
Change from baseline The semi-structured scale for functional evaluation of personal neglect at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Barrage Test at 2 weeks and 4 weeks
|
Barrage test (0-36). High score means a better outcome. |
Change from baseline Barrage Test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Letter cancellation test at 2 weeks and 4 weeks
|
Letter cancellation test - (0-104). High score means a better outcome. |
Change from baseline Letter cancellation test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Sentence reading test at 2 weeks and 4 weeks
|
Sentence reading test (0-6). High score means a worse outcome. |
Change from baseline Sentence reading test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline Wundt-Jastrow area illusion test at 2 weeks and 4 weeks
|
Wundt-Jastrow area illusion test (0-20). High score means a worse outcome. |
Change from baseline Wundt-Jastrow area illusion test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Zeitfenster: Change from baseline The semi structured scale for the functional evaluation of extrapersonal neglect at 2 weeks and 4 weeks
|
The semi structured scale for the functional evaluation of extrapersonal neglect (0-9). High score means a worse outcome. |
Change from baseline The semi structured scale for the functional evaluation of extrapersonal neglect at 2 weeks and 4 weeks
|
|
Neurophysiological outcome
Zeitfenster: Change from baseline oscillation at 2 weeks and 4 weeks
|
The ratio of fast (8-30 Hz, α-β) to slow (2-8 Hz, δ-θ) oscillation amplitude at the midline electrodes (Fz, Cz, Pz, Oz) will be measured and compared pre- and post intervention." |
Change from baseline oscillation at 2 weeks and 4 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Caregiver psychological distress
Zeitfenster: Change from baseline Back depression Inventory II at 2 weeks and 4 weeks
|
Back depression Inventory II (BDI II) - (0-63). High score means a worse outcome. |
Change from baseline Back depression Inventory II at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Zeitfenster: Change from baseline State-trait anxiety inventory; at 2 weeks and 4 weeks
|
State-trait anxiety inventory (STAI-Y). It is composed by two scales: STAI-Y State (20-80) and STAI-Y Trait (20-80). High score means a worse outcome. |
Change from baseline State-trait anxiety inventory; at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Zeitfenster: Change from baseline Questionario psicofisiologico (CBA) at 2 weeks and 4 weeks
|
Psychophysiological Questionnaire (30-120). WHOQOL-BREF. |
Change from baseline Questionario psicofisiologico (CBA) at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Zeitfenster: Change from baseline Prolonged grief disorder -12 at 2 weeks and 4 weeks
|
Prolonged grief disorder -12 (PG-12) - (11-55). High score means a worse outcome. |
Change from baseline Prolonged grief disorder -12 at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Zeitfenster: Change from baseline Family strain questionnaire at 2 weeks and 4 weeks
|
Family strain questionnaire (FSQ) - (1-44). High score means a worse outcome. |
Change from baseline Family strain questionnaire at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Zeitfenster: Change from baseline Wolrd health organization - quality of life at 2 weeks and 4 weeks
|
better outcome. |
Change from baseline Wolrd health organization - quality of life at 2 weeks and 4 weeks
|
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Zerebrovaskuläre Erkrankungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Psychische Störungen
- Neurobehaviorale Manifestationen
- Neurokognitive Störungen
- Kommunikationsstörungen
- Sprachstörungen
- Sprachstörungen
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Streicheln
- Aphasie
- Bewusstseinsstörungen
Andere Studien-ID-Nummern
- 345
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .